Trial · NCT03121534
Adverse events67
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 67
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Alanine aminotransferase increased | Investigations | Ibrutinib, Nivolumab and Blinatumomab | 2 | 9 | 2 |
| other | Alkaline phosphatase increased | Investigations | Ibrutinib, Nivolumab and Blinatumomab | 3 | 9 | 3 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Anorexia | Gastrointestinal disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Aspartate aminotransferase increased | Investigations | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Blood bilirubin increased | Investigations | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Bruising | Skin and subcutaneous tissue disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Chills | General disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Confusion | Psychiatric disorders | Ibrutinib, Nivolumab and Blinatumomab | 2 | 9 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Creatinine increased | Investigations | Ibrutinib, Nivolumab and Blinatumomab | 2 | 9 | 2 |
| other | Cytokine release syndrome | Immune system disorders | Ibrutinib, Nivolumab and Blinatumomab | 2 | 9 | 2 |
| other | Dysgeusia | Nervous system disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Dysphasia | Nervous system disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Edema | General disorders | Ibrutinib, Nivolumab and Blinatumomab | 2 | 9 | 3 |
| other | Erectile dysfunction | Reproductive system and breast disorders | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
| other | Fall | Injury, poisoning and procedural complications | Ibrutinib, Nivolumab and Blinatumomab | 1 | 9 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03121534/events